Sionna (NASDAQ: SION) cuts about 46% of staff and narrows focus to one CF drug pair

Posted by Jeff Wilder on Nov 10th, 2026

What happened

Sionna Therapeutics, Inc. (NASDAQ: SION) cut about 46% of its workforce in September to focus on one cystic fibrosis drug pair. The pair is SION-451, an NBD1 stabilizer, and SION-2222, also called galicaftor.

In its third-quarter report on Nov. 10, the company said it is not advancing SION-719 as an add-on to standard of care. The PreciSION CF Phase 2a trial of SION-719 added to Trikafta missed its key activity endpoint.

Cash, cash equivalents and marketable securities totaled $249.8 million on Sept. 30. By OptimistFi's calculation, that is down $60.5 million, or 19.5%, from $310.3 million on Dec. 31, 2025. Sionna expects this cash to fund operations into the second half of 2029.

Key numbers

Metric	Latest	Change	Source
Net loss, Q3 2026	$32.4 million	from $20.3 million, +$12.1 million	SEC 8-K, Exhibit 99.1; change calculated from SEC 8-K
Research and development expense, Q3 2026	$22.0 million	from $16.0 million, +$6.0 million	SEC 8-K, Exhibit 99.1; change calculated from SEC 8-K
General and administrative expense, Q3 2026	$12.8 million	from $7.8 million, +$5.0 million	SEC 8-K, Exhibit 99.1; change calculated from SEC 8-K
Cash, cash equivalents and marketable securities, Sept. 30, 2026	$249.8 million		SEC 8-K, Exhibit 99.1
Change in cash and marketable securities since Dec. 31, 2025	-$60.5 million	-19.5%	Calculated from SEC 8-K

Where the wider loss came from

Net loss for the third quarter was $32.4 million, up $12.1 million from $20.3 million a year earlier. Research and development expense rose to $22.0 million from $16.0 million, up $6.0 million. General and administrative expense rose to $12.8 million from $7.8 million, up $5.0 million.

Interest income fell to $2.4 million from $3.5 million, which also widened the loss. For the nine months ended Sept. 30, net loss was $89.1 million against $54.8 million a year earlier. Loss per share for the quarter was $0.72, compared with $0.46.

Sionna says the research and development increase came mainly from development expenses, personnel costs including stock-based pay, and restructuring costs from the job cuts. It says the general and administrative increase came mainly from personnel costs and the same restructuring costs. Restructuring costs are a one-time item, so they do not show spending after the cuts.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What the dual combination rests on

The case for SION-451 + SION-2222 leans on analyses of the failed SION-719 trial. Post hoc analyses excluded three participants whose drug levels were consistent with missed doses. They showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L when SION-719 was added to Trikafta. Sionna believes that points to NBD1 biological activity.

Sionna also chose the pair based on clinical, pharmacokinetic and nonclinical data. That includes safety, tolerability and pharmacokinetic goals met in a Phase 1 trial in healthy volunteers. A poster at the North American Cystic Fibrosis Conference in Atlanta in October showed NBD1 stabilizer combinations improving CFTR trafficking and function up to wild-type levels in primary human bronchial epithelial cells.

The AscenSION CF trial is open-label. Participants with CF homozygous for F508del will switch from Trikafta and take the pair for 28 days. The trial will assess sweat chloride, safety and pharmacokinetics. Its design builds in lessons from PreciSION CF on dosing adherence and sweat chloride variability.

Why it matters

OptimistFi has argued that Sionna is a binary bet. It must prove its CFTR-normalizing medicines deliver differentiated clinical benefit before cash burn forces unattractive financing. The cuts and the runway help on financing, but the clinical case now rests on a trial that has not started. The report leaves the case mixed.

The company's own risk list cuts against the lead program. The filing says post hoc analyses are exploratory and may not reliably predict future outcomes. It also warns that in vitro and preclinical data may not translate to clinical benefit, and that results from one compound may not predict results for a different compound or combination.

Sionna also lists as risks its ability to achieve the restructuring savings and to keep key staff after the cuts.

What's next

Sionna plans to start the AscenSION CF Phase 2 proof-of-concept trial in the first quarter of 2027. Its sweat chloride results will be the first test of whether the post hoc signal from SION-719 carries over to the pair.

A late start, or a weak sweat chloride result, would weaken the case and leave the cash runway as the main support. An on-time start followed by a clear sweat chloride reduction would strengthen it.